| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
Critical Brand Investments And Operational Efficiencies Set To Spur Robust Growth And Investor Confidence
J&J spinoff
Kenvue Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.86 |
| 52 Week High | US$23.00 |
| 52 Week Low | US$17.67 |
| Beta | 0 |
| 11 Month Change | 8.75% |
| 3 Month Change | 24.99% |
| 1 Year Change | 7.32% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -15.02% |
Recent News & Updates
Kenvue (NYSE:KVUE) Has A Pretty Healthy Balance Sheet
Sep 08
Kenvue: Promising Steps Toward Long-Term Success
Aug 11Recent updates
Kenvue (NYSE:KVUE) Has A Pretty Healthy Balance Sheet
Sep 08Kenvue: Promising Steps Toward Long-Term Success
Aug 11Kenvue Is A Premier Consumer Company, But I Am Waiting For A Lower Price Before I Buy
Aug 02Is There An Opportunity With Kenvue Inc.'s (NYSE:KVUE) 36% Undervaluation?
Jul 15Kenvue: A 4% Yield Worth Going Long
Jun 12Kenvue's (NYSE:KVUE) Soft Earnings Don't Show The Whole Picture
May 21Kenvue Q1 Earnings Preview: A Potentially Troubling Trend
May 03Kenvue: Fairly Valued Spinout
Apr 17Is Kenvue Inc. (NYSE:KVUE) Trading At A 31% Discount?
Apr 08Kenvue: This Dividend Newcomer Is Worth A Look
Feb 13Kenvue: What To Expect From Its First Full-Year Report As A Standalone Company
Feb 05Kenvue: Portfolio Filled Of Market Leaders
Dec 20Kenvue Inc.'s (NYSE:KVUE) Intrinsic Value Is Potentially 42% Above Its Share Price
Dec 07Kenvue: Dude, Where's My Dividend Growth?
Nov 26Kenvue: Only A Watchlist Stock For Now
Nov 19There May Be Some Bright Spots In Kenvue's (NYSE:KVUE) Earnings
Nov 10Kenvue: Consumer Health Giant's Journey From IPO To Legal Challenges And Beyond
Oct 19Kenvue: Interesting Times
Sep 18Kenvue: Charting A Healthy Future In Consumer Health
Sep 06Kenvue Split-Off: Still Undecided? 3 (And A Half) Aspects To Consider
Aug 16Kenvue: A Buffett-Style Investment At A Reasonable Price
Jul 11Johnson & Johnson Spinoff Kenvue Is Worth Owning - But Maybe Not Yet
Jun 13Shareholder Returns
| KVUE | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 4.1% | -2.2% | -4.4% |
| 1Y | 7.3% | -18.4% | 19.1% |
Return vs Industry: KVUE exceeded the US Personal Products industry which returned -18.4% over the past year.
Return vs Market: KVUE underperformed the US Market which returned 19.1% over the past year.
Price Volatility
| KVUE volatility | |
|---|---|
| KVUE Average Weekly Movement | 5.2% |
| Personal Products Industry Average Movement | 9.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KVUE has not had significant price volatility in the past 3 months.
Volatility Over Time: KVUE's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 22,000 | Thibaut Mongon | www.kenvue.com |
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Kenvue Inc. Fundamentals Summary
| KVUE fundamental statistics | |
|---|---|
| Market cap | US$43.78b |
| Earnings (TTM) | US$1.12b |
| Revenue (TTM) | US$15.48b |
39.1x
P/E Ratio2.8x
P/S RatioIs KVUE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KVUE income statement (TTM) | |
|---|---|
| Revenue | US$15.48b |
| Cost of Revenue | US$6.58b |
| Gross Profit | US$8.90b |
| Other Expenses | US$7.78b |
| Earnings | US$1.12b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.58 |
| Gross Margin | 57.51% |
| Net Profit Margin | 7.23% |
| Debt/Equity Ratio | 82.2% |
How did KVUE perform over the long term?
See historical performance and comparison